Back to search results

CHORUS+ Study: PrEP and MOUD Access for People Who Inject Drugs

This study, called CHORUS+, is looking at ways to help people who inject drugs get access to HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). PrEP is a daily medicine that can prevent HIV infection. The study will involve a peer recovery coach who will use motivational interviewing to encourage people to take PrEP and MOUD. You might be able to join if you are 18 or older, have injected opioids in the last 6 months, can speak English, plan to live in Boston for 6 months, and are medically cleared for PrEP and MOUD (meaning your kidney function and other lab tests are normal). The main goal is to see how well people stick to taking PrEP after 6 months. The study is currently unclear on its recruitment status and plans to enroll 284 participants.

Study design
This is an interventional study that will compare the CHORUS+ behavioral intervention with standard care. It plans to enroll 284 participants.
What's involved
You would participate in a baseline interview with a peer recovery coach. You would also need to provide contact information for two family members or friends and sign medical record release forms.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures adherence to HIV PrEP at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05769218

PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study

Recruiting
NAAges 18+InterventionalTreatment
Boston Medical Center
~284 participants
Updated 2026-04-06 on ClinicalTrials.gov
What's tested:CHORUS+Standard of care

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence to HIV PrEP at 6 months Adherence to HIV PrEP
Measured over 6 months

Conditions

Opioid Use Disorder

Explore related trials

HIV InfectionOpioid Use Disorder

Where it's being run

2 sites across 1 states
Massachusetts2

Study leadership

  • Sabrina A Assoumou, MD MPH · PRINCIPAL_INVESTIGATOR · Boston Medical Center, Infectious Diseases

Who to contact

Sabrina A Assoumou, MD MPH
[email protected]
617-414-2857
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Injected opioids within the past 6 months (by self-report)
Willingness to provide contact information for two family members or friends
Willingness to sign medical records release forms
Ability to speak English
Plans to reside in Boston area for the next 6 months
Are medically cleared to take PrEP and MOUD (normal renal and PrEP-related labs)

Exclusion

Persons with previous HIV diagnosis (by self-report; confirmed via HIV test result)
Express desire to harm themselves or others
Individuals who are pregnant at baseline
Individuals who are already enrolled in an interventional study

What this trial measures

  • Adherence to HIV PrEP at 6 months Adherence to HIV PrEP6 months

    This outcome will be assessed by the proportion of individuals who have dried blood spot tenofovir-diphosphate (TFV-DP) blood level 700 fmol/punch or greater at 6 months post-enrollment.